Le marché des tests d'antigène leucocytaire humain (HLA) devrait atteindre 1 155,65 millions de dollars US d'ici 2028, contre 697,74 millions de dollars US en 2021 ; il devrait enregistrer un TCAC de 7,5 % de 2022 à 2028.
Les antigènes leucocytaires humains jouent un rôle essentiel dans la réponse immunitaire de l'organisme aux substances externes. La principale utilisation des tests HLA est de faire correspondre les receveurs de greffes d’organes et de tissus avec des donneurs compatibles. Les tests HLA impliquent également de rechercher chez les receveurs de greffe la présence d'anticorps susceptibles de cibler le tissu ou l'organe donné dans le cadre d'une réponse immunitaire.
Le rapport offre des informations et une analyse approfondie du marché des tests d’antigène leucocytaire humain (HLA), en mettant l’accent, entre autres, sur les tendances du marché, les progrès technologiques et la dynamique du marché. Il fournit également une analyse du paysage concurrentiel des principaux acteurs du marché mondial. En outre, il inclut l’impact de la pandémie de COVID-19 sur le marché dans toutes les grandes régions. La pandémie de COVID-19 a créé à la fois une crise de santé publique et une crise économique à l’échelle mondiale. Avant la pandémie, le marché des tests d’antigène leucocytaire humain (HLA) était en croissance continue en raison de la régularité de l’évaluation des donneurs d’organes, des consolations et des traitements. La première vague de COVID-19 a perturbé les consultations, les suivis et les dépistages liés aux maladies autres que la COVID-19. Plusieurs entreprises ont subi de lourdes pertes au dernier trimestre 2019 ; la pandémie a particulièrement eu des effets néfastes sur le marché mondial au cours des premier et deuxième trimestres 2020. Les entreprises du monde entier ont été freinées par la perturbation des chaînes d’approvisionnement et la demande accrue de produits et services de santé. Pour réduire l’infection au COVID-19 dans les hôpitaux et les cliniques, les professionnels de la santé et les patients ont adopté et préféré traiter leurs patients à distance. Ces circonstances imprévisibles ont également entravé les procédures de transplantation d’organes. De nombreux traitements chirurgicaux et consultations non urgentes ont été annulés ou reportés, et les interventions chirurgicales électives ont été suspendues dans de nombreux établissements afin de limiter la propagation du SRAS-CoV-2 ainsi que de réserver et de réaffecter les ressources, notamment le personnel de santé (infirmières et anesthésistes), les médecins et les médecins. équipements (équipements de protection individuelle et ventilateurs) et lits. La recommandation de « rester à la maison » a entraîné une réduction significative des opérations de don d'organes et de transplantation d'organes. Ces conditions ont freiné la croissance du marché mondial des tests d'antigène leucocytaire humain (HLA) en 2020.
Aperçus stratégiques
Régions lucratives pour le marché des tests d'antigène leucocytaire humain (HLA)
Aperçu du marché
Le nombre croissant de procédures de don de plasma et de transplantation d'organes stimule la croissance du marché
Les antigènes des leucocytes humains (HLA) sont des protéines spécialisées présentes sur toutes les surfaces cellulaires. du corps humain, à l’exception des globules rouges. Les tests HLA ont une application significative dans la transplantation d'organes, qui peuvent être recommandés dans le cadre du traitement de l'insuffisance rénale, de la cirrhose chronique du foie et des maladies cardiaques chroniques, entre autres problèmes médicaux. La prévalence croissante des maladies chroniques et des défaillances d’organes entraîne une forte demande de procédures de transplantation d’organes, ainsi que de tests HLA. Avant la transplantation, des tests HLA sont effectués pour vérifier la compatibilité tissulaire entre les patients et les donneurs afin d'éviter le rejet du greffon. Ces dernières années, la transplantation est devenue une pratique réussie dans le monde entier. Selon les données publiées dans l’Observatoire mondial du don et de la transplantation (GODT), en 2020, 129 681 transplantations d’organes ont été enregistrées au total. Parmi ceux-ci, 31,7 % étaient des greffes de rein vivant et 20,40 % des greffes de foie vivant.
Les gouvernements de divers pays prennent des initiatives pour sensibiliser à la nécessité du don d'organes et aux avantages de la transplantation d'organes dans certaines procédures de traitement. . Par exemple, le Réseau d’approvisionnement et de transplantation d’organes (OPTN) a mis en œuvre quelques stratégies pour améliorer le nombre de procédures de transplantation d’organes aux États-Unis. Ces stratégies se concentrent sur l’augmentation du nombre de greffes d’organes et de tissus chez les patients atteints d’une maladie organique en phase terminale, sur la modification de la répartition actuelle des organes et sur la modification de la liste d’attente pour les transplantations d’organes en redistribuant les réserves d’organes existantes. De plus, l’OPTN a utilisé des stratégies originales pour améliorer la transplantation d’organes. Ces stratégies innovantes incluent l'utilisation optimisée des organes obtenus à partir de patients décédés [par exemple, don après mort cardiaque (DCD) ou donneurs en état de mort cérébrale], la réduction des rejets d'organes, la promotion du don vivant et l'amélioration du taux d'autorisation potentielle de don d'organes. ;
Ainsi, la demande croissante de transplantation d'organes conduit à la nécessité d'un nombre plus important de kits et de consommables de test HLA, ce qui stimule la croissance du marché des tests HLA.
Produit et informations basées sur les services
En fonction des produits et des services, l'antigène leucocytaire humain ( Le marché des tests HLA) est segmenté en réactifs et consommables, instruments, logiciels et services. En 2021, le segment des réactifs et consommables détenait la plus grande part du marché et devrait enregistrer le TCAC le plus rapide de 7,5 % au cours de la période de prévision.
Marché des tests d'antigène leucocytaire humain (HLA), par produit et services - 2022 et 2028
Informations basées sur la technologie
Sur la base de la technologie, le marché des tests d'antigène leucocytaire humain (HLA) est segmenté en technologies d'analyse moléculaire et en technologies non technologies d’analyse moléculaire. En 2021, le segment des technologies d'analyse moléculaire détenait la plus grande part du marché et il devrait enregistrer un TCAC plus élevé de 7,7 % entre 2022 et 2028.
Informations basées sur l'utilisateur final
< p>En fonction de l’utilisateur final, le marché des tests d’antigène leucocytaire humain (HLA) est segmenté en laboratoires de référence indépendants, hôpitaux et centres de transplantation, etc. En 2021, le segment des laboratoires de référence indépendants détenait la plus grande part du marché. Cependant, le segment des hôpitaux et des centres de transplantation devrait afficher le TCAC le plus élevé de 7,9 % entre 2022 et 2028.Les acteurs du marché des tests d'antigène leucocytaire humain (HLA) adoptent des stratégies organiques telles que le lancement et l'expansion de produits pour étendre leur et son portefeuille de produits dans le monde entier, tout en répondant à la demande croissante de produits.
Par géographie
Sur la base de la géographie, le marché des tests d'antigène leucocytaire humain (HLA) est segmenté en Amérique du Nord (États-Unis). , Canada et Mexique), Europe (Royaume-Uni, Allemagne, France, Italie, Espagne et reste de l'Europe), Asie-Pacifique (Chine, Japon, Inde, Australie, Corée du Sud et reste de l'Asie-Pacifique), Moyen-Orient Est etamp; L'Afrique (les Émirats arabes unis, l'Arabie saoudite, l'Afrique du Sud et le reste du Moyen-Orient et de l'Afrique), ainsi que les pays du Sud et de l'Afrique. Amérique centrale (Brésil, Argentine et reste de l'Amérique du Sud et de l'Amérique centrale).
Profils d'entreprise
- Thermo Fisher Scientific Inc.
- CareDx
- Qiagen
- Illumina Inc.
- Bio-Rad Laboratories, Inc.
- TBG Diagnostics Limited
- F .Hoffmann-La Roche Ltd.
- Takara Bio Inc.
- Luminex Corporation
- Omixon Inc.
- Le centre de séquençage
- Protrans
- HistoGenetics LLC.
- CD Genomics
- Qunitara Biosciences
- CeGat GmbH
- Creative Biolabs Inc.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Human leukocyte antigens play an essential part in the body's immune response to external substances. The principal use for human leukocyte antigen (HLA) testing is to match organ and tissue transplant recipients with compatible donors. HLA testing also involves screening transplant recipients for the presence of antibodies that might target the donated tissue or organ as part of an immune response.
Increasing plasma donation and organ transplants procedures is one of the most significant factors responsible for the overall market growth.
Based on product and service type, reagent and consumables took the forefront leaders in the worldwide market by accounting largest share in 2021 and is expected to continue to do so till the forecast period.
The molecular assay technologies segment dominated the global human leukocyte antigen (HLA) testing market and is likely to account for the revenue of US$ 626.86 million in 2022.
Thermo Fisher Scientific, Inc., CareDx, Inc., Qiagen N.V., Illumina, Bio-Rad Laboratories, Inc., TGB Diagnostics Ltd., F. Hoffman La-Roche Ltd., Takara Bio, Luminex Corporation, Oximon, The Sequencing Center, Protrans, HistoGenetics LLC, CD Genomics, Quintara Biosciences, CeGaT GmbH, Creative Biolabs, Inc., are among the leading companies operating in the global human leukocyte antigen (HLA) testing market
Global human leukocyte antigen (HLA) testing market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for human leukocyte antigen (HLA) testing market. The US is estimated to hold the largest share in the human leukocyte antigen (HLA) testing market during the forecast period. The presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, the increasing number of technological advancements is the key factor responsible for the Asia-Pacific regional growth for human leukocyte antigen (HLA) testing accounting fastest growth of the region during the coming years.
The List of Companies - Human Leukocyte Antigen (HLA) Market
- Thermo Fisher Scientific Inc.
- CareDx
- Qiagen
- Illumina Inc.
- Bio-Rad Laboratories, Inc.
- TBG Diagnostics Limited
- F.Hoffmann-La Roche Ltd.
- Takara Bio Inc.
- Luminex Corporation
- Omixon Inc.
- The Sequencing Center
- Protrans
- HistoGenetics LLC.
- CD Genomics
- Qunitara Biosciences
- CeGat GmbH
- Creative Biolabs Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
May 2022
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
May 2022
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
May 2022
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
May 2022
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
May 2022
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
May 2022
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
May 2022
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)